August 27, 2004

Seroquel Approved for Bipolar Mania

AstraZeneca (AZN) announced that the U.S. Food and Drug Administration (FDA) has approved additional efficacy labeling information based on 12-week data for Seroquel (quetiapine fumarate), a psychotropic medication indicated for the treatment of acute manic episodes associated with bipolar I disorder.

The data, part of the large scale effort to examine the use of Seroquel in bipolar disorder, showed that after 12 weeks, approximately two thirds of patients receiving Seroquel achieved remission.


Post a comment

Type the characters you see in the picture above.

Remember Me?